Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Suzette Girgis"'
Autor:
Xin Miao, Jenna D. Goldberg, Jennifer Smit, Jeffery S. Russell, Raluca Verona, Tara Stephenson, Suzette Girgis, Tineke Casneuf, Kodandaram Pillarisetti, Arnob Banerjee, Brandi Hilder, Yang Chen, Damien Fink, Diego Vieyra, Shun Xin Wang Lin
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 21:S39-S40
Background B-cell maturation antigen (BCMA, CD269), a single transmembrane protein, can be shed as a soluble 6 kilodalton protein fragment (sBCMA) upon cleavage at the transmembrane domain by γ-secretase. Given its selective expression in the B-cell
Autor:
Clarissa M. Uhlar, Jesús F. San-Miguel, Lotfi Benboubker, Saad Z. Usmani, Maria-Victoria Mateos, Alfred L. Garfall, Hareth Nahi, Rachel Kobos, Philippe Moreau, Rian Van Rampelbergh, Britta Besemer, Amrita Krishnan, Lionel Karlin, Jenna D. Goldberg, Laura Rosiñol, Suzette Girgis, Joaquin Martinez-Lopez, Nizar J. Bahlis, Niels W.C.J. van de Donk, Ajay K. Nooka, Albert Oriol, Lixia Pei, Thomas Martin, Arnob Banerjee, Raluca Verona, Yunsi Olyslager, Mindy Jaffe, Ajai Chari, Danielle Trancucci, Surbhi Sidana, Tara Stephenson, Rakesh Popat
Publikováno v:
Blood. 138:896-896
Introduction: Teclistamab (JNJ-64007957) is a T-cell redirecting, bispecific IgG4 antibody that targets both B-cell maturation antigen (BCMA) and CD3 receptors to induce T-cell mediated cytotoxicity of BCMA-expressing myeloma cells. Teclistamab is un
Autor:
Paula Rodriguez-Otero, Amrita Krishnan, Brandi Hilder, Elham Askari, Xuewen Ma, Shiyi Yang, Ajai Chari, Jenna D. Goldberg, Luciano J. Costa, Maria-Victoria Mateos, Suzette Girgis, Monique C. Minnema, Jesus G. Berdeja, Niels W.C.J. van de Donk, Jeffery S. Russell, Albert Oriol, Raluca Verona
Publikováno v:
Blood. 138:158-158
Introduction: Despite recent advances in treatment, patients with multiple myeloma (MM) continue to relapse. G protein-coupled receptor family C group 5 member D (GPRC5D) is a promising target for immunotherapy in patients with MM due to its high exp
Autor:
Brandi Hilder, Paula Rodriguez, Albert Oriol, Jesus G. Berdeja, Maria-Victoria Mateos, Suzette Girgis, Jeffery S. Russell, Raluca Verona, Thomas J. Prior, Monique C. Minnema, Ajai Chari, Niels W.C.J. van de Donk, Elham Askari, Amrita Krishnan, Jenna D. Goldberg
Publikováno v:
Blood. 136:40-41
Despite improved outcomes with current MM treatments, most patients (pts) will develop refractory disease, highlighting the need for novel treatments. GPRC5D is an orphan receptor whose transcript is highly expressed in primary MM cells but has gener
Autor:
Amrita Krishnan, Ajai Chari, Jesús F. San-Miguel, Tara Stephenson, Maria-Victoria Mateos, Niels W.C.J. van de Donk, Laura Rosiñol, Lotfi Benboubker, Albert Oriol, Hareth Nahi, Alfred L. Garfall, Lionel Karlin, Manisha Bhutani, Suzette Girgis, Saad Z. Usmani, Raluca Verona, Arnob Banerjee, Jenna D. Goldberg, Lixia Pei
Publikováno v:
Journal of Clinical Oncology. 39:8007-8007
8007 Background: BCMA-targeted immunotherapies offer considerable promise for relapsed/refractory MM. Teclistamab (JNJ-64007957) is a BCMA × CD3 bispecific IgG4 antibody that redirects CD3+ T cells to BCMA-expressing MM cells. We present updated res
Autor:
Thomas J. Prior, Monique C. Minnema, Ajai Chari, Suzette Girgis, Niels W.C.J. van de Donk, Paula Rodriguez-Otero, Amrita Krishnan, Maria-Victoria Mateos, Jesus G. Berdeja, Luciano J. Costa, Elham Askari, Jenna D. Goldberg, Jeffery S. Russell, Raluca Verona, Brandi Hilder, Albert Oriol
Publikováno v:
Journal of Clinical Oncology. 39:8008-8008
8008 Background: New immunotherapy targets in MM are needed as patients (pts) continue to relapse. The orphan receptor GPRC5D is expressed on malignant plasma cells in MM. Talquetamab (JNJ-64407564) is a bispecific IgG4 antibody that redirects T cell
Autor:
Maria-Victoria Mateos, Saad Z. Usmani, Arnob Banerjee, Jenna D. Goldberg, Jesús F. San Miguel, Laura Rosiñol, Tara Stephenson, Shun Xin Wang Lin, Albert Oriol, Alfred L. Garfall, Ajai Chari, Suzette Girgis, Kristy Kemmerer, Jennifer Smit, Niels W.C.J. van de Donk, Jeffrey R. Infante, Yusri Elsayed, Hareth Nahi, Amrita Krishnan, Homer Adams
Publikováno v:
Journal of Clinical Oncology. 38:100-100
100 Background: Teclistamab (JNJ-64007957) is a bispecific BCMA x CD3 antibody that induces T cell-mediated cytotoxicity against BCMA-expressing myeloma cells. Initial results from an ongoing study of teclistamab in RRMM (NCT03145181) are presented.